Manufacturers of materia medica products engaged in the introduction of new products to commerce by advertising are subjected to an enormous expense which, in order to make the investment of capital remunerative, must be met by profit on sales. At the present time it costs no less than from fifty to a hundred thousand dollars in advertising before a new product can return a sufficient margin of profit to pay reasonable interest on the investment. Every new product introduced means an enormous outlay and a tremendous risk to the manufacturer. As this advertising is exclusively confined to the medical press, it means an enormous donation to the medical journals ofthe country.
Under such circumstances, it is not surprising that the manufacturing houses and medical press favor the continuance of materia medica monopoly, although this is contrary to the principles of fraternalism distinguishing the medical profession from the times of Hippocrates.
STEWART FE. THE RELATION OF THE PATENT AND TRADEMARK LAWS TO MATERIA MEDICA NOMENCLATURE. JAMA. 1912;LIX(11):836–839. doi:10.1001/jama.1912.04270090080003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: